Global Blood Therapeutics, Inc. (NASDAQ:GBT) – Analysts at Wedbush reduced their FY2017 earnings per share estimates for shares of Global Blood Therapeutics in a report released on Monday. Wedbush analyst L. Moussatos now anticipates that the company will earn ($2.51) per share for the year, down from their previous estimate of ($2.34). Wedbush currently has a “Outperform” rating and a $73.00 price target on the stock. Wedbush also issued estimates for Global Blood Therapeutics’ Q4 2017 earnings at ($0.69) EPS, FY2018 earnings at ($2.99) EPS, FY2019 earnings at ($3.77) EPS, FY2020 earnings at ($3.39) EPS and FY2021 earnings at ($1.56) EPS.

A number of other research analysts have also commented on the company. Cowen reissued a “buy” rating and set a $83.00 price objective on shares of Global Blood Therapeutics in a report on Thursday, November 9th. Zacks Investment Research lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Oppenheimer set a $53.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th. SunTrust Banks increased their price objective on Global Blood Therapeutics to $67.00 and gave the company a “buy” rating in a report on Monday, November 6th. Finally, Morgan Stanley reissued an “overweight” rating and set a $56.00 price objective (up previously from $51.00) on shares of Global Blood Therapeutics in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating and fourteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $56.38.

Global Blood Therapeutics (NASDAQ GBT) opened at $40.00 on Wednesday. Global Blood Therapeutics has a 52-week low of $13.35 and a 52-week high of $43.95.

Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same period in the prior year, the business earned ($0.58) earnings per share.

Several hedge funds have recently made changes to their positions in GBT. BNP Paribas Arbitrage SA lifted its position in shares of Global Blood Therapeutics by 694.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock worth $124,000 after acquiring an additional 3,975 shares during the period. Legal & General Group Plc lifted its position in shares of Global Blood Therapeutics by 10.1% in the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock worth $178,000 after acquiring an additional 440 shares during the period. Jane Street Group LLC bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter worth approximately $200,000. Trexquant Investment LP bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter worth approximately $202,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter worth approximately $205,000. Institutional investors own 90.48% of the company’s stock.

In other Global Blood Therapeutics news, VP Peter Radovich sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the sale, the vice president now owns 2,684 shares of the company’s stock, valued at approximately $93,940. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles J. Homcy sold 70,000 shares of the firm’s stock in a transaction that occurred on Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now directly owns 83,328 shares in the company, valued at approximately $2,830,652.16. The disclosure for this sale can be found here. Insiders sold a total of 88,500 shares of company stock worth $3,003,350 in the last ninety days. Insiders own 5.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Global Blood Therapeutics, Inc. (GBT) to Post FY2017 Earnings of ($2.51) Per Share, Wedbush Forecasts” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/06/global-blood-therapeutics-inc-gbt-to-post-fy2017-earnings-of-2-51-per-share-wedbush-forecasts.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.